Applied Materials (NASDAQ:AMAT) Sets New 12-Month High After Analyst Upgrade
Applied Materials, Inc. (NASDAQ:AMAT – Get Free Report) reached a new 52-week high during mid-day trading on Thursday after Susquehanna raised their price target on the stock from $435.00 to $500.00. Susquehanna currently has a positive rating on the stock. Applied Materials traded as high as $396.25 and last traded at $394.7250, with a volume […]
Serica Energy (LON:SQZ) Reaches New 52-Week High After Analyst Upgrade
Serica Energy plc (LON:SQZ – Get Free Report)’s stock price reached a new 52-week high during trading on Monday after Stifel Nicolaus raised their price target on the stock from GBX 266 to GBX 281. Stifel Nicolaus currently has a buy rating on the stock. Serica Energy traded as high as GBX 287.50 and last […]
Cenovus Energy (TSE:CVE) Hits New 12-Month High After Analyst Upgrade
Shares of Cenovus Energy Inc. (TSE:CVE – Get Free Report) (NYSE:CVE) hit a new 52-week high during mid-day trading on Monday after Raymond James Financial raised their price target on the stock from C$33.00 to C$42.00. The stock traded as high as C$38.50 and last traded at C$37.56, with a volume of 5544232 shares. The […]
APA (NASDAQ:APA) Hits New 52-Week High After Analyst Upgrade
APA Corporation (NASDAQ:APA – Get Free Report) shares hit a new 52-week high on Monday after Morgan Stanley raised their price target on the stock from $22.00 to $43.00. Morgan Stanley currently has an underweight rating on the stock. APA traded as high as $45.66 and last traded at $44.5680, with a volume of 2495919 […]
Cheniere Energy (NYSE:LNG) Hits New 52-Week High After Analyst Upgrade
Cheniere Energy, Inc. (NYSE:LNG – Get Free Report) shares hit a new 52-week high during trading on Monday after JPMorgan Chase & Co. raised their price target on the stock from $279.00 to $338.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Cheniere Energy traded as high as $300.89 and last […]
Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week High After Analyst Upgrade
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) shares reached a new 52-week high during trading on Thursday after HC Wainwright raised their price target on the stock from $48.00 to $56.00. HC Wainwright currently has a buy rating on the stock. Enliven Therapeutics traded as high as $36.72 and last traded at $35.53, with […]
last updated on 9 Apr 18:20